FDA-Approved Medications to Treat Tardive Dyskinesia

Research output: Contribution to journalArticle

Abstract

Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.

Original languageEnglish (US)
JournalThe Journal of clinical psychiatry
Volume81
Issue number1
DOIs
StatePublished - Dec 17 2019

Fingerprint

Medication Adherence
Dyskinesias
Dopamine Receptors
Therapeutics
Antipsychotic Agents
Quality of Life
Tardive Dyskinesia
Guidelines
valbenazine
deutetrabenazine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

FDA-Approved Medications to Treat Tardive Dyskinesia. / McEvoy, Joseph P.

In: The Journal of clinical psychiatry, Vol. 81, No. 1, 17.12.2019.

Research output: Contribution to journalArticle

@article{f9164643671a43c795aa96c28fb3d98c,
title = "FDA-Approved Medications to Treat Tardive Dyskinesia",
abstract = "Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.",
author = "McEvoy, {Joseph P.}",
year = "2019",
month = "12",
day = "17",
doi = "10.4088/JCP.NU18041BR3C",
language = "English (US)",
volume = "81",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - FDA-Approved Medications to Treat Tardive Dyskinesia

AU - McEvoy, Joseph P.

PY - 2019/12/17

Y1 - 2019/12/17

N2 - Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.

AB - Tardive dyskinesia (TD), a condition characterized by involuntary movements, is found in patients taking antipsychotics or other agents that block dopamine receptors. Symptoms of TD are associated with reduced quality of life, psychosocial problems, and medication nonadherence. Few agents tested in the treatment of TD had sufficient data to support or refute their use, until recently. A review of new evidence was combined with the existing guideline to provide new treatment recommendations. This activity provides an overview of treatments for patients with TD, including valbenazine and deutetrabenazine, which both received FDA approval for the treatment of TD.

UR - http://www.scopus.com/inward/record.url?scp=85076977070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076977070&partnerID=8YFLogxK

U2 - 10.4088/JCP.NU18041BR3C

DO - 10.4088/JCP.NU18041BR3C

M3 - Article

C2 - 31851437

AN - SCOPUS:85076977070

VL - 81

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 1

ER -